57 related articles for article (PubMed ID: 22588077)
1. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.
Hanley PJ; Lam S; Shpall EJ; Bollard CM
J Vis Exp; 2012 May; (63):e3627. PubMed ID: 22588077
[TBL] [Abstract][Full Text] [Related]
2. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
Adhikary D; Behrends U; Feederle R; Delecluse HJ; Mautner J
J Virol; 2008 Apr; 82(8):3903-11. PubMed ID: 18272580
[TBL] [Abstract][Full Text] [Related]
3. Analysis and Development of Antigen-specific T Cells Derived from Peripheral Blood Mononuclear Cells of Healthy Donors.
Kim J; Jung S; Jeong BK; Kim KA; Jisu J; Bang WS; Ham B; Kim JY; Kim YA; Lee HJ
Anticancer Res; 2024 Apr; 44(4):1377-1387. PubMed ID: 38537976
[TBL] [Abstract][Full Text] [Related]
4. Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotype.
Masiello F; Tirelli V; Sanchez M; van den Akker E; Gabriella G; Marconi M; Villa MA; Rebulla P; Hashmi G; Whitsett C; Migliaccio AR
Transfusion; 2014 Apr; 54(4):1059-70. PubMed ID: 24004289
[TBL] [Abstract][Full Text] [Related]
5. Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L; Chen N; Dai L; Peng X
iScience; 2023 Nov; 26(11):108192. PubMed ID: 38026157
[TBL] [Abstract][Full Text] [Related]
6. Decontamination of Two Umbilical Cord Blood Grafts Prior to Autologous Administration.
Stancioiu F; Bogdan R; Bulumac B; Ivanescu B; Dumitrescu R
Maedica (Bucur); 2022 Dec; 17(4):885-892. PubMed ID: 36818273
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.
Garcia-Aponte OF; Herwig C; Kozma B
J Biol Eng; 2021 Apr; 15(1):13. PubMed ID: 33849630
[TBL] [Abstract][Full Text] [Related]
8. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.
Abraham AA; John TD; Keller MD; Cruz CRN; Salem B; Roesch L; Liu H; Hoq F; Grilley BJ; Gee AP; Dave H; Jacobsohn DA; Krance RA; Shpall EJ; Martinez CA; Hanley PJ; Bollard CM
Blood Adv; 2019 Jul; 3(14):2057-2068. PubMed ID: 31292125
[TBL] [Abstract][Full Text] [Related]
9. HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.
Sung JA; Patel S; Clohosey ML; Roesch L; Tripic T; Kuruc JD; Archin N; Hanley PJ; Cruz CR; Goonetilleke N; Eron JJ; Rooney CM; Gay CL; Bollard CM; Margolis DM
Mol Ther; 2018 Oct; 26(10):2496-2506. PubMed ID: 30249388
[TBL] [Abstract][Full Text] [Related]
10. Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.
de Koning C; Admiraal R; Nierkens S; Boelens JJ
Blood Adv; 2018 Feb; 2(4):428-432. PubMed ID: 29487057
[TBL] [Abstract][Full Text] [Related]
11. Virus-Specific T Cells for the Immunocompromised Patient.
Houghtelin A; Bollard CM
Front Immunol; 2017; 8():1272. PubMed ID: 29075259
[TBL] [Abstract][Full Text] [Related]
12. Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.
Fesnak AD; Hanley PJ; Levine BL
Curr Hematol Malig Rep; 2017 Aug; 12(4):335-343. PubMed ID: 28762038
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.
Servais S; Hannon M; Peffault de Latour R; Socie G; Beguin Y
Stem Cell Investig; 2017; 4():40. PubMed ID: 28607914
[TBL] [Abstract][Full Text] [Related]
14. Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.
Dave H; Luo M; Blaney JW; Patel S; Barese C; Cruz CR; Shpall EJ; Bollard CM; Hanley PJ
Mol Ther Methods Clin Dev; 2017 Jun; 5():13-21. PubMed ID: 28480300
[TBL] [Abstract][Full Text] [Related]
15. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).
Haverkos BM; Coleman C; Gru AA; Pan Z; Brammer J; Rochford R; Mishra A; Oakes CC; Baiocchi RA; Freud AG; Porcu P
Discov Med; 2017 Mar; 23(126):189-199. PubMed ID: 28472613
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S; Nicholas SK; Martinez CA; Leen AM; Hanley PJ; Gottschalk SM; Rooney CM; Hanson IC; Krance RA; Shpall EJ; Cruz CR; Amrolia P; Lucchini G; Bunin N; Heimall J; Klein OR; Gennery AR; Slatter MA; Vickers MA; Orange JS; Heslop HE; Bollard CM; Keller MD
J Allergy Clin Immunol; 2016 May; 137(5):1498-1505.e1. PubMed ID: 26920464
[TBL] [Abstract][Full Text] [Related]
17. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV.
Daenthanasanmak A; Salguero G; Sundarasetty BS; Waskow C; Cosgun KN; Guzman CA; Riese P; Gerasch L; Schneider A; Ingendoh A; Messerle M; Gabaev I; Woelk B; Ruggiero E; Schmidt M; von Kalle C; Figueiredo C; Eiz-Vesper B; von Kaisenberg C; Ganser A; Stripecke R
Mol Ther Methods Clin Dev; 2015; 1():14060. PubMed ID: 26052526
[TBL] [Abstract][Full Text] [Related]
18. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.
Hanley PJ; Melenhorst JJ; Nikiforow S; Scheinberg P; Blaney JW; Demmler-Harrison G; Cruz CR; Lam S; Krance RA; Leung KS; Martinez CA; Liu H; Douek DC; Heslop HE; Rooney CM; Shpall EJ; Barrett AJ; Rodgers JR; Bollard CM
Sci Transl Med; 2015 Apr; 7(285):285ra63. PubMed ID: 25925682
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.
Hanley PJ; Bollard CM; Brunstein CG
Cytotherapy; 2015 Jun; 17(6):749-755. PubMed ID: 25632003
[TBL] [Abstract][Full Text] [Related]
20. Controlling cytomegalovirus: helping the immune system take the lead.
Hanley PJ; Bollard CM
Viruses; 2014 May; 6(6):2242-58. PubMed ID: 24872114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
